Loading…
Loading…
MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.
Factors such as the prospect of slow dividend growth could make Medtronic stock less attractive to income-focused investors. For investors interested in both income and capital growth, much suggests that Medtronic remains a strong choice to buy and hold over the next few years.
Medtronic is one of the world's largest medical device companies. Medtronic has reshaped its business, with a focus on returning to growth.
California State Teachers Retirement System increased its holdings in Medtronic PLC (NYSE: MDT) by 7,655.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 158,124,578 shares of the medical technology company's stock after buying an additional 156,085,748 shares during the
Medtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
Medtronic plc (MDT) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Let's look beyond recent obstacles these companies have encountered.
MDT's stronger growth and earnings outlook improve its case, but margin, currency and execution risks keep investors selective.